Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Ikeda, Masafumi
Ikeda, Kenji
Kudo, Masatoshi
Osaki, Yukio
Okusaka, Takuji
Tamai, Toshiyuki
Suzuki, Takuya
Hisai, Takashi
Miyagishi, Hideaki
Okita, Kiwamu
Kumada, Hiromitsu
机构：
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
[2] Toranomon Gen Hosp, Tokyo, Japan
[3] Kinki Univ, Sch Med, Osakasayama, Osaka, Japan
[4] Osaka Red Cross Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[5] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[6] Eisai & Co Ltd, Tokyo, Japan
[7] Shunan Mem Hosp, Kudamatsu, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.309
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
309
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I dose escalation study of E7080, a novel anti-angiogenic multikinase inhibitor, in Japanese patients with advanced solid tumors
    Yamada, K.
    Fujiwara, Y.
    Yamamoto, N.
    Yamada, Y.
    Suzuki, S.
    Kobayashi, N.
    Koizumi, F.
    Nishio, K.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).
    Harding, James J.
    Do, Richard K. G.
    Hollywood, Ellen
    Uhlitskykh, Khrystyna
    Valentino, Emily
    Wan, Peter Justin
    Hamilton, Casey R.
    Frick, Jessica
    Feng, Xiaoxing
    Johnston, Amanda
    Bomalaski, John S.
    Li, Chien-Feng
    O'Reilly, Eileen Mary
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Harding, James J.
    Kelley, Robin Kate
    Tan, Benjamin R.
    Iobst, Emily
    Boussayoud, Chayma
    Muenkel, Kerri E.
    Do, Richard K. G.
    Chou, Joanne F.
    Capanu, Marinela
    Ruiz, Carmen
    Lee, Mariam Rodriguez
    Wilton, John
    Iyer, Renuka V.
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [35] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Tanwandee, Tawesak
    Sukeepaisarnjaroen, Wattana
    Chan, Stephen Lam
    Choo, SuPin
    Han, Guohong
    Sriuranpong, Virote
    Pan, Hongming
    Yau, Thomas Cheung
    Ren, Zhenggang
    Xu, Jian-Ming
    Peng, Bin
    Saji, Takami
    Sun, Yongjian
    Huang, Alan
    Manenti, Luigi
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    O'Neil, Bert H.
    Bendell, Johanna C.
    Modiano, Manuel R.
    Machiels, Jean-Pascal H.
    Versola, Melissa Jo
    Hodge, Jeff Paul
    Sawarna, Karen
    Tse, Nielson
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [38] A phase 2 study of galunisertib (TGF-B R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Gane, Edward
    Assenat, Eric
    Siebler, Jurgen
    Galle, Peter R.
    Merle, Philippe
    Ollivier-Hourmand, Isabelle
    Cleverly, Ann
    Gueorguieva, Ivelina
    Lahn, Michael M. F.
    Faivre, Sandrine J.
    Benhadji, Karim A.
    Giannelli, Gianluigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [40] Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
    O'Neil, Bert H.
    Goff, Laura W.
    Kauh, John Sae Wook
    Strosberg, Jonathan R.
    Bekaii-Saab, Tanios S.
    Lee, Ruey-min
    Kazi, Aslamuzzaman
    Moore, Dominic T.
    Learoyd, Maria
    Lush, Richard M.
    Sebti, Said M.
    Sullivan, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2350 - 2356
12345